Aldeyra Therapeutics (ALDX) Non-Current Debt (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Non-Current Debt came in at $15.0 million in Q4 2025, little changed YoY from $15.0 million in Q4 2024, and little changed on a QoQ basis from $15.0 million in Q3 2025.
Aldeyra Therapeutics (ALDX) Non-Current Debt (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 13 years of Non-Current Debt data on file, last reported at $15.0 million in Q4 2025.
- Quarterly Non-Current Debt changed 0.0% year-over-year to $15.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.0 million (changed 0.0% YoY) and the FY2025 annual result came in at $15.0 million, changed 0.0% from the prior year.
- Non-Current Debt steadied at $15.0 million in Q4 2025, from $15.0 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $15.4 million in Q3 2021 to a low of $2.7 million in Q3 2023.
- A 5-year average of $14.0 million and a median of $15.0 million in 2021 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2023 — Non-Current Debt slumped 82.29% — and 2024, when it surged 464.51%.
- Tracing ALDX's Non-Current Debt over 5 years: stood at $15.0 million in 2021, then retreated by 0.51% to $14.9 million in 2022, then sank by 82.19% to $2.7 million in 2023, then surged by 464.51% to $15.0 million in 2024, then changed by 0.0% to $15.0 million in 2025.
- The last three Non-Current Debt figures came in at $15.0 million (Q4 2025), $15.0 million (Q3 2025), and $15.1 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.00 Mn |
| Dec 31, 2025 | 15.00 Mn |
| Sep 30, 2025 | 15.00 Mn |
| Mar 31, 2025 | 15.10 Mn |
| Dec 31, 2024 | 15.00 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Sep 30, 2023 | 2.66 Mn |
| Jun 30, 2023 | 10.13 Mn |
| Mar 31, 2023 | 15.00 Mn |
| Dec 31, 2022 | 14.92 Mn |
| Sep 30, 2022 | 15.00 Mn |
| Jun 30, 2022 | 15.00 Mn |
| Mar 31, 2022 | 15.00 Mn |
| Dec 31, 2021 | 15.00 Mn |
| Sep 30, 2021 | 15.42 Mn |
| Jun 30, 2021 | 15.34 Mn |
| Mar 31, 2021 | 15.00 Mn |
| Dec 31, 2020 | 15.00 Mn |
| Sep 30, 2020 | 12.69 Mn |
| Jun 30, 2020 | 15.00 Mn |